• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大环环尺寸对含吡啶螯合剂中 [Pb]Pb(II) 配合物稳定性影响的评价。

Evaluation of the Effect of Macrocyclic Ring Size on [Pb]Pb(II) Complex Stability in Pyridyl-Containing Chelators.

机构信息

Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.

Life Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada.

出版信息

Inorg Chem. 2022 Jun 27;61(25):9638-9649. doi: 10.1021/acs.inorgchem.2c01114. Epub 2022 Jun 15.

DOI:10.1021/acs.inorgchem.2c01114
PMID:35704752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9366509/
Abstract

As an element-equivalent theranostic pair, lead-203 (Pb, 100% EC, half-life = 51.92 h) and lead-212 (Pb, 100% β, half-life = 10.64 h), through the emission of γ rays and an α particle in its decay chain, respectively, can aid in the development of personalized targeted radionuclide treatment for advanced and currently untreatable cancers. With these isotopes currently being used in clinical trials, an understanding of the relationship between the chelator structure, ability to incorporate the radiometal, and metal-complex stability is needed to help design appropriate chelators for clinical use. Herein, we report an investigation into the effect of ring size in macrocyclic chelators where pyridine, an intermediate Lewis base, acts as an electron donor toward lead. Crown-4Py (4,7,13,16-tetrakis(pyridin-2-ylmethyl)-1,10-dioxa-4,7,13,16-tetraazacyclooctadecane), cyclen-4Py (1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane), and NOON-2Py (7,16-bis(pyridin-2-ylmethyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane) were synthesized and analyzed for their ability to coordinate Pb. Metal complex stability was investigated via [Pb]Pb radiolabeling studies, H NMR spectroscopy, X-ray crystallography, and potentiometry. With the smallest macrocyclic backbone, cyclen-4Py had the highest radiochemical yield, while, in descending order, crown-4Py and NOON-2Py had the lowest. Thermodynamic stability constants (log ) of 19.95(3), 13.29(5), and 11.67 for [Pb(Cyclen-4Py)], [Pb(Crown-4Py)], and [Pb(NOON-2Py)], respectively, correlated with their radiochemical yields. The X-ray crystal structure of the least stable complexes [Pb(NOON-2Py)] revealed a hemidirected Pb center, as reflected by a void within the coordination sphere, and [Pb(Crown-4Py)] showed an average Pb-N pyridine interatomic distance of >3 Å. By contrast, the crystal structure of [Pb(Cyclen-4Py)] showed shorter Pb-N pyridine interactions, and in solution, only one highly symmetric isomer existed for this complex, whereas conformational flexibility was observed for both [Pb(Crown-4Py)] and [Pb(NOON-2Py)] at the NMR timescale. This study illustrates the importance of the macrocyclic backbone size when incorporating bulky electron-donor groups into the design of a macrocyclic chelator as it affects the accessibility of lead to the donor arms. Our results show that cyclen-4Py is a promising chelator for future studies with this theranostic pair.

摘要

作为一种元素等效的治疗诊断双模态系统,铅-203(Pb,100% EC,半衰期=51.92 h)和铅-212(Pb,100%β,半衰期=10.64 h),分别通过其衰变链中γ射线和α粒子的发射,可辅助开发针对晚期和目前无法治疗的癌症的个性化靶向放射性核素治疗。随着这些同位素目前正在临床试验中使用,需要了解螯合剂结构、掺入放射性金属的能力以及金属配合物稳定性之间的关系,以帮助设计用于临床使用的适当螯合剂。在此,我们报告了在大环螯合剂中研究环大小的影响,其中吡啶是一种中间路易斯碱,可作为铅的电子供体。冠-4Py(4,7,13,16-四(吡啶-2-基甲基)-1,10-二氧杂-4,7,13,16-四氮杂环十八烷)、环烯-4Py(1,4,7,10-四(吡啶-2-基甲基)-1,4,7,10-四氮杂环十二烷)和 NOON-2Py(7,16-双(吡啶-2-基甲基)-1,4,10,13-四氧杂-7,16-二氮杂环十八烷)被合成并分析其与 Pb 的配位能力。通过[Pb]Pb 放射性标记研究、1H NMR 光谱、X 射线晶体学和电位法研究了金属配合物的稳定性。具有最小大环骨架的环烯-4Py 具有最高的放射化学产率,而冠-4Py 和 NOON-2Py 的放射化学产率则依次降低。热力学稳定常数(log)分别为 19.95(3)、13.29(5)和 11.67,分别为[Pb(Cyclen-4Py)]、[Pb(Crown-4Py)]和[Pb(NOON-2Py)]。X 射线晶体结构表明,最不稳定的配合物[Pb(NOON-2Py)]中 Pb 中心呈半指向性,反映在配位球内有空隙,而[Pb(Crown-4Py)]则显示 Pb-N 吡啶的平均原子间距离>3 Å。相比之下,[Pb(Cyclen-4Py)]的 X 射线晶体结构显示出较短的 Pb-N 吡啶相互作用,并且在溶液中,该配合物仅存在一种高度对称的异构体,而[Pb(Crown-4Py)]和[Pb(NOON-2Py)]在 NMR 时间尺度上表现出构象灵活性。这项研究说明了在设计大环螯合剂时将大体积供电子基团纳入设计时大环骨架大小的重要性,因为它会影响铅与供体臂的可及性。我们的结果表明,环烯-4Py 是该治疗诊断双模态系统未来研究的有前途的螯合剂。

相似文献

1
Evaluation of the Effect of Macrocyclic Ring Size on [Pb]Pb(II) Complex Stability in Pyridyl-Containing Chelators.大环环尺寸对含吡啶螯合剂中 [Pb]Pb(II) 配合物稳定性影响的评价。
Inorg Chem. 2022 Jun 27;61(25):9638-9649. doi: 10.1021/acs.inorgchem.2c01114. Epub 2022 Jun 15.
2
Capturing Mercury-197m/g for Auger Electron Therapy and Cancer Theranostic with Sulfur-Containing Cyclen-Based Macrocycles.用含硫环戊二烯基大环配合物捕获汞-197m/g 进行俄歇电子治疗和癌症治疗诊断。
Inorg Chem. 2024 Jul 29;63(30):14241-14255. doi: 10.1021/acs.inorgchem.4c02418. Epub 2024 Jul 18.
3
Tuning the Softness of the Pendant Arms and the Polyazamacrocyclic Backbone to Chelate the Pb/Pb Theranostic Pair.调节悬垂臂的柔软度和多氮大环骨架以螯合 Pb/Pb 治疗 pair。
Inorg Chem. 2024 Jan 29;63(4):1745-1758. doi: 10.1021/acs.inorgchem.3c02610. Epub 2024 Jan 17.
4
Coordination Behavior of 1,4-Disubstituted Cyclen Endowed with Phosphonate, Phosphonate Monoethylester, and H-Phosphinate Pendant Arms.具有膦酸酯、膦酸单乙酯和 H-膦酸酯侧臂的 1,4-二取代环戊烷的配位行为。
Molecules. 2019 Sep 12;24(18):3324. doi: 10.3390/molecules24183324.
5
New bis-, tris- and tetrakis(pyrazolyl)borate ligands with 3-pyridyl and 4-pyridyl substituents: synthesis and coordination chemistry.带有3-吡啶基和4-吡啶基取代基的新型双、三及四(吡唑基)硼酸酯配体:合成与配位化学
Dalton Trans. 2005 Jun 7(11):1910-23. doi: 10.1039/b502892b. Epub 2005 Apr 28.
6
Tetra-2,3-pyrazinoporphyrazines with externally appended pyridine rings. 5. Synthesis, physicochemical and theoretical studies of a novel pentanuclear palladium(II) complex and related mononuclear species.带有外部连接吡啶环的四 - 2,3 - 吡嗪并卟啉嗪。5. 一种新型五核钯(II)配合物及相关单核物种的合成、物理化学和理论研究。
Inorg Chem. 2008 May 5;47(9):3903-19. doi: 10.1021/ic702430j.
7
Getting a lead on Pb-amide chelators for Pb radiopharmaceuticals.寻找用于放射性 Pb 药物的 Pb-酰胺螯合剂的先导化合物。
Dalton Trans. 2021 Sep 7;50(33):11579-11595. doi: 10.1039/d1dt01653a. Epub 2021 Aug 5.
8
Production, purification, and radiolabeling of the Pb/Pb theranostic pair.Pb/Pb诊疗组合的制备、纯化及放射性标记
EJNMMI Radiopharm Chem. 2021 Feb 1;6(1):6. doi: 10.1186/s41181-021-00121-4.
9
Macrocyclic receptor showing extremely high Sr(II)/Ca(II) and Pb(II)/Ca(II) selectivities with potential application in chelation treatment of metal intoxication.大环受体表现出对 Sr(II)/Ca(II) 和 Pb(II)/Ca(II) 的极高选择性,具有在金属中毒螯合治疗中的应用潜力。
Inorg Chem. 2011 Apr 18;50(8):3772-84. doi: 10.1021/ic200182e. Epub 2011 Mar 17.
10
Mn(2+) complexes with pyridine-containing 15-membered macrocycles: thermodynamic, kinetic, crystallographic, and (1)H/(17)O relaxation studies.含吡啶的 15 元大环锰(Ⅱ)配合物:热力学、动力学、晶体学和(1)H/(17)O 弛豫研究。
Inorg Chem. 2010 Apr 5;49(7):3224-38. doi: 10.1021/ic9020756.

引用本文的文献

1
Pb in targeted radionuclide therapy: a review.靶向放射性核素治疗中的铅:综述
EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.
2
18-membered macrocycle appended on resin for selective rare earth element extraction and separation.连接在树脂上的18元大环用于选择性稀土元素萃取和分离。
Commun Chem. 2025 Jun 5;8(1):176. doi: 10.1038/s42004-025-01565-4.
3
Theoretical Study of Metal-Ligand Interactions in Lead Complexes with Radiopharmaceutical Interest.具有放射性药物应用价值的铅配合物中金属-配体相互作用的理论研究。

本文引用的文献

1
Revisiting Lead(II)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic Acid Coordination Chemistry in Aqueous Solutions: Evidence of an Underestimated Thermodynamic Stability.重新审视水溶液中铅(II)-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸的配位化学:热力学稳定性被低估的证据。
ACS Omega. 2022 Apr 29;7(18):15596-15602. doi: 10.1021/acsomega.2c00387. eCollection 2022 May 10.
2
Targeted -Emitter Therapy with Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.采用 Pb-DOTAMTATE 的靶向发射治疗治疗转移性 SSTR 表达神经内分泌肿瘤:首例人体剂量递增临床试验。
J Nucl Med. 2022 Sep;63(9):1326-1333. doi: 10.2967/jnumed.121.263230. Epub 2022 Jan 6.
3
Molecules. 2024 Sep 4;29(17):4198. doi: 10.3390/molecules29174198.
4
Chelation of [In]In with the dual-size-selective macrocycles py-macrodipa and py-macrodipa.用双尺寸选择性大环 py-macrodipa 和 py-macrodipa 对 [In]In 进行螯合。
Dalton Trans. 2024 Sep 10;53(35):14634-14647. doi: 10.1039/d4dt02146k.
5
The DOTA macrocyclic cavity in metallic radiopharmaceuticals: Mythology or reality?金属放射性药物中的DOTA大环腔:神话还是现实?
EJNMMI Radiopharm Chem. 2023 Aug 3;8(1):17. doi: 10.1186/s41181-023-00202-6.
6
Diagnostic and Therapeutic Radiopharmaceuticals.诊断与治疗用放射性药物
ACS Pharmacol Transl Sci. 2022 Sep 19;5(10):835-837. doi: 10.1021/acsptsci.2c00173. eCollection 2022 Oct 14.
Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.应用治疗诊断偶联物进行放射剂量计算时的物理、化学和生物学意义。
Theranostics. 2022 Jan 1;12(1):232-259. doi: 10.7150/thno.62851. eCollection 2022.
4
Getting a lead on Pb-amide chelators for Pb radiopharmaceuticals.寻找用于放射性 Pb 药物的 Pb-酰胺螯合剂的先导化合物。
Dalton Trans. 2021 Sep 7;50(33):11579-11595. doi: 10.1039/d1dt01653a. Epub 2021 Aug 5.
5
Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles' heel of antibiotic-resistant microbes.基于铁依赖性(抗生素耐药微生物的致命弱点)的新型宿主导向疗法的铁螯合抗感染药物。
Environ Chem Lett. 2021;19(4):2789-2808. doi: 10.1007/s10311-021-01242-7. Epub 2021 Apr 23.
6
Production, purification, and radiolabeling of the Pb/Pb theranostic pair.Pb/Pb诊疗组合的制备、纯化及放射性标记
EJNMMI Radiopharm Chem. 2021 Feb 1;6(1):6. doi: 10.1186/s41181-021-00121-4.
7
Synthesis and Evaluation of a Macrocyclic Actinium-225 Chelator, Quality Control and In Vivo Evaluation of Ac-crown-αMSH Peptide.大环鐠-225 螯合剂的合成与评价,Ac-crown-αMSH 肽的质量控制和体内评价。
Chemistry. 2020 Sep 4;26(50):11435-11440. doi: 10.1002/chem.202002999. Epub 2020 Aug 28.
8
Theranostic radiopharmaceuticals: established agents in current use.诊疗用放射性药物:当前正在使用的已确立的药物。
Br J Radiol. 2018 Nov;91(1091):20170969. doi: 10.1259/bjr.20170969. Epub 2018 Mar 12.
9
The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair Y and Y.核医学中诊疗一体化方法的起源与发展,以放射性核素对Y和Y为例
Pharmaceuticals (Basel). 2017 Jun 20;10(2):56. doi: 10.3390/ph10020056.
10
Targeted Radionuclide Therapy: Practical Applications and Future Prospects.靶向放射性核素治疗:实际应用与未来展望。
Biomark Cancer. 2016 May 18;8(Suppl 2):35-8. doi: 10.4137/BIC.S31804. eCollection 2016.